CClinicalTrials.gg
CompletedNCT05158881Updated Dec 15, 2021

Near-infrared Spectroscopy in Cerebral Oxygenation Monitoring in Full Term Neonates

An observational study in Cerebral Oxygenation in Full-term Neonates, sponsored by Marwa Mohamed Farag. Completed at 1 site in Egypt. Open to participants aged 0 Minutes to 10 Minutes, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-15.

Sponsored by Marwa Mohamed Farag · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
0 Minutes to 10 Minutes
Sex
All
01

Study summary

The aim of the study was to assess the values of cerebral oxygenation in full-term neonates in the first 10 minutes of life and to compare these values between neonates delivered by normal vaginal delivery and those delivered by elective cesarean section.

02

Conditions studied

  • Cerebral Oxygenation in Full-term Neonates
03

In context

Lead sponsor

Marwa Mohamed Farag is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Minutes to 10 Minutes
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Full term neonates born either via normal vaginal delivery or elective cesarean section.

Inclusion criteria

  • Gestational age ≥38 weeks, without any medical support and normal pregnancy development.

Exclusion criteria

Exclusion Criteria:

  • Newborns with gestational age \<38 weeks.
  • Newborns with intrauterine growth restriction.
  • Evidence of perinatal depression (hypoxic ischemic encephalopathy).
  • The need for respiratory support or oxygen therapy in the first 10 minutes of life.
  • Suspected or known brain malformations or congenital cyanotic heart disease.
  • Birth complications (e.g. vacuum extraction or forceps application).
  • Newborn delivered through cesarean section with previous attempts of normal vaginal delivery.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (actual)
Patient registry
No

Groups and cohorts

  • Neonates delivered by normal vaginal delivery

    Device: Near-infrared spectroscopy

  • Neonates delivered by elective cesarean section.

    Device: Near-infrared spectroscopy

Interventions

  • DeviceNear-infrared spectroscopy

    Near-infrared spectroscopy (NIRS) offers the non-invasive continuous monitoring of cerebral oxygenation and perfusion. Cerebral regional oxygen (crSO2) measured via NIRS represents a mixed tissue saturation value, thus enabling information on the balance of cerebral oxygen delivery and oxygen consumption.

06

What researchers measure

Primary outcomes

  1. Cerebral regional oxygen saturation monitoring (crSO2)

    Measurements was done by using Near infrared spectroscopy (INVOSTM 5100C Cerebral/ Somatic Oximeter Monitor; Covidien) by placing a neonatal brain sensor on the left frontoparietal area of the newborn's head.

    Time frame: the first 10 minutes of life

  2. Peripheral oxygen saturation monitoring (SpO2)

    Oxygen saturation was measured using pulse oximeter (Masimo or Nellcor) by applying a preductal pulseoximetry sensor to the right wrist.

    Time frame: the first 10 minutes of life

  3. Blood gas analysis

    It was performed from umbilical cord blood. All newborns will be clinically observed and evaluated during this period by a neonatologist, and clinical status will be assessed by Apgar score. The Apgar score is based on a total score of 1 to 10. The higher the score, the better the baby is doing after birth. A score of 7, 8, or 9 is normal and is a sign that the newborn is in good health.

    Time frame: up to 10 minutes of life

  4. Fractional tissue oxygen extraction (FTOE)

    After measuring peripheral oxygen saturation (SpO2) and cerebral regional oxygen saturation (crSO2). For evaluation of the balance of oxygen delivery and oxygen consumption, calculation of the fractional tissue oxygen extraction can be done using the following equation: FTOE=(SpO2-crSO2)/SpO2

    Time frame: up to 10 minutes of life

07

Study locations

1 site
  • Neonatal Intensive Care Unit (NICU) of Alexandria University Maternity Hospital.
    Alexandria, 21131, Egypt
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05158881
Lead sponsor
Marwa Mohamed Farag
Responsible party
Marwa Mohamed Farag (Lecturer in Pediatrics, Faculty of Medicine, Alexandria University) — Sponsor-investigator
First posted
Dec 15, 2021
Start date
Jan 10, 2021
Primary completion
Jun 2, 2021
Completion
Jun 30, 2021
Last update
Dec 15, 2021

Study contacts

Alaa IA Ibrahim, MBBCh
principal investigator · Faculty of Medicine, Alexandria University, Egypt
Hesham A Ghazal, PhD
study director · Faculty of Medicine, Alexandria University, Egypt
Marwa M Farag, PhD
study chair · Faculty of Medicine, Alexandria University, Egypt
Bahaa S Hammad
study director · Faculty of Medicine, Alexandria University, Egypt

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion